MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
Since its foundation in 1999, MMV and partners have developed and brought to registration four new medicines: Pyramax® , (pyronaridine-artesunate) co-developed with Shin Poong; Eurartesim®  (dihydroartemisinin-piperaquine) with Sigma-Tau; Guilin’s artesunate injection  for the treatment of severe malaria, Artesun®; and Coartem® Dispersible  (artemether-lumefantrine), a child-friendly formulation developed with Novartis. Since 2009, over 250 million courses of Coartem Dispersible treatment have been supplied to 50 malaria-endemic countries; and since prequalification in 2010, an estimated 25 million vials of artesunate injection have been delivered, saving 165,000 additional lives.
Managing the largest portfolio  of antimalarial R&D projects ever assembled, of over 65 projects, MMV has nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s success in research and access & product management comes from its extensive partnership network  of over 375 pharmaceutical, academic and endemic-country partners in 50 countries.
MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.
For further information please contact:
Jaya Banerji 
Director, Advocacy & Communications
Tel: +41 22 555 0327
Mob: +41 79 707 7181
email: banerjij [at] mmv [dot] org